The positive Phase 3 extension study data for modified-release hydrocortisone, developed by Diurnal Limited, a subsidiary of Neurocrine Biosciences, is likely to have a positive short-term impact on the stock price of Neurocrine Biosciences (NBIX). The successful presentation at ENDO 2023 indicates progress in the development of the drug, which could potentially lead to regulatory approval and commercialization, benefiting the company's revenues and growth prospects.